RC48
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations (NCT05847764) | Sun Yat-sen University | 2023-05-01 |
Track RC48 automatically
Every clearance here is in the API, with alerts when new ones post.